Skip to main content
. 2013 Sep;346(3):465–472. doi: 10.1124/jpet.113.205732

Fig. 4.

Fig. 4.

NLRP1 caspase-5 and caspase-1 activity in cisplatin-induced AKI. (A) NLRP1 protein was increased in the kidney on day 3 of cisplatin-induced AKI (Cis). *P < 0.01 vs. Veh, Day 1, Day 2. (B) NLRP1 protein was decreased in NLRP3−/− mice on day 3 of cisplatin-induced AKI compared with WT mice. *P < 0.05 vs. WT Cis. (C) Caspase-5 protein and (D) caspase-5 activity were increased in cisplatin-induced AKI. In densitometric analysis of the immunoblots, the data are presented as protein/actin ratios plotted on the y-axis. β-actin, used as a loading control, was not different between the groups. Representative immunoblots are derived from at least three separate experiments. *P < 0.05 vs. Veh (vehicle). (E) Caspase-1 activity was increased in cisplatin-induced AKI in both wild-type and NLRP3−/− mice compared with vehicle treated mice. n = 4 per group. *P < 0.01 vs. Veh.